ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...

> Ambrilia Biopharma reported positive 24-week Phase III top-line results for prolonged-release formulation of Octreotide. Release

> Amarin is raising $60 million through a stock placement. Release

> Acorda Therapeutics CEO Ron Cohen has exercised stock options for 31,432 shares. Report

> A federal proposal requiring drug and device makers to disclose payments to doctors got a boost yesterday when Eli Lilly became the first Big Pharma to back it. Lilly report

> In an interesting twist on the usual generics news, it's the copycat makers who are predicted to suffer as competitors undercut their products. The source of this competition? None other than China. Generics report

> The NIH's Avastin/Lucentis trial could fundamentally reshape relations between payers and pharma, according to IMS Health. Report

> After weeks of pressure from Congress to request more money for the agency--and weeks of refusals to specify a figure for beefing up FDA's safety operations-FDA commissioner Andrew von Eschenbach has asked lawmakers for $275 million. FDA report

And Finally... South Korean officials have wiped out the poultry population of Seoul in an effort to combat the spread of the avian flu virus. Report

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.